acat

ACAT-IN-1 cis isomer is a potent ACAT inhibitor (IC50: 100 nM) used for the study of immune system-related diseases.

Lecimibide (DuP 128) is a potent and selective inhibitor of acyl coenzyme A:cholesterol acyltransferase (ACAT), useful for studying high-lipid-related diseases.

Monatepil maleate (AJ-2615 maleate) is an orally active Ca2+-channel and α1-adrenoceptor antagonist and non-competitive heparanoyl-coenzyme A:cholesterol acyltransferase (ACAT) inhibitor with antihypertensive activity.Monatepil maleate is used in studies of hyperlipidemia and atherosclerosis. Monatepil maleate is used to study hyperlipidemia and atherosclerosis.

Monatepil 2maleate is an orally active Ca2+-channel antagonist and ACAT inhibitor with alpha(1)-adrenergic receptor blocking activity and antiarrhythmic properties that inhibit vasoconstriction.Monatepil 2maleate may be used to study atherosclerosis.

Eflucimibe (L0081) is an acyl coenzyme A: cholesterol acyltransferase inhibitor for the treatment of cardiovascular disease and endocrine and metabolic disorders, and can be used to study atherosclerosis and hyperlipidemia.

TMP-153 is a novel and potent ACAT inhibitor with an IC50 value of 5-10 nM for intestinal and hepatic ACAT in animals.TMP-153 has a hypocholesterolemic effect, inhibiting cholesterol uptake and lowering plasma cholesterol in rats and hamsters.

YM17E is an inhibitor of ACAT with IC50 of 44 nM in rabbit liver microsomes in vitro.

Beauvericin, a Fusarium mycotoxin, inhibits acyl-CoA:cholesterol acyltransferase (ACAT) in rat liver microsomal enzyme assays with an IC50 value of 3 μM.

Rimonabant (SR141716) is an inverse agonist for the cannabinoid receptor CB1. It is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. Its main avenue of effect is a reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States.

YM-750 is a potent inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT), with an IC50 value of 0.18 μM. ACAT is an enzyme that catalyzes the conversion of cholesterol and long-chain fatty-acyl-coenzyme A into cholesteryl esters.

Avasimibe (PD-148515) is an orally bioavailable inhibitor of acyl-Coenzyme A: cholesterol acyltransferase (ACAT, IC50: 3.3 μM) that prevents cholesterol deposition in the arterial wall. It also inhibits human P450 isoenzymes CYP2C9/1A2/2C19 (IC50: 2.9/13.9/26.5 μM).

ACAT-IN-10 dihydrochloride is a compound that serves as an inhibitor of acyl-Coenzyme A: cholesterol acyltransferase (ACAT).ACAT-IN-10 dihydrochloride effectively hampers NF-κB mediated transcription, albeit to a lesser extent.

ACAT-IN-5 (example 19) is an inhibitor of acyl-Coenzyme A: cholesterol acyltransferase (ACAT) that effectively suppresses NF-κB-mediated transcription.

ACAT-IN-8 (example 206) is a compound that inhibits acyl-Coenzyme A: cholesterol acyltransferase (ACAT), an enzyme involved in cholesterol modulation, and also inhibits NF-κB-mediated transcription.

ACAT-IN-7 is a compound that acts as an inhibitor of acyl-Coenzyme A: cholesterol acyltransferase (ACAT) enzyme. It effectively suppresses the transcription process mediated by NF-κB.

ACAT-IN-9, acts as an inhibitor of acyl-Coenzyme A: cholesterol acyltransferase (ACAT). By doing so, it effectively suppresses NF-κB mediated transcription.

ACAT-IN-4 hydrochloride (Example 208) is a potent inhibitor of acyl-Coenzyme A: cholesterol acyltransferase (ACAT) in its hydrochloride salt form, effectively hindering NF-κB mediated transcription.

ACAT-IN-2 is a potent inhibitor of acyl-Coenzyme A: cholesterol acyltransferase (ACAT). This compound effectively blocks NF-κB mediated transcription.

ACAT-IN-3, a potent inhibitor of acyl-Coenzyme A: cholesterol acyltransferase (ACAT), effectively suppresses NF-κB dependent transcription.

ACAT-IN-10 is an acyl-Coenzyme A: cholesterol acyltransferase (ACAT) inhibitor that exhibits weak inhibitory activity on NF-κB-mediated transcription.

ACAT-IN-6, an acyl-Coenzyme A: cholesterol acyltransferase (ACAT) inhibitor, displays potent inhibition of NF-κB mediated transcription.

ACAT-IN-4 (Example 208) is a chemical inhibitor of acyl-Coenzyme A: cholesterol acyltransferase (ACAT) and effectively inhibits NF-κB-mediated transcription.

Saracatinib (AZD0530) (AZD0530) is an effective Src inhibitor (IC50: 2.7 nM), and effective to Lck, Fyn, Lyn, Blk, Fgr and c-Yes.

Indacaterol (Onbrez; Arcapta) is a β2-Adrenergic Agonist. The mechanism of action of indacaterol is as an Adrenergic beta2-Agonist.